Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial symbols : Cytk save search
Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
CYTK | $67.49 0.73% 0.73% 1.5M
|
Health Technology
|
| O: -3.34%
H: 3.39%
C: 2.51%
congress heart trial cardiology
Cytokinetics Presents New Data at CMR 2024 From FOREST-HCM, the Open Label Extension Clinical Trial of Aficamten
Published: 2024-01-25 (Crawled : 12:30) - globenewswire.com
CYTK | $67.49 0.73% 0.73% 1.5M
|
Health Technology
|
| O: 1.43%
H: 0.96%
C: -0.04%
label extension trial
Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
Published: 2023-12-27 (Crawled : 12:30) - globenewswire.com
CYTK | $67.49 0.73% 0.73% 1.5M
|
Health Technology
|
| O: 61.12%
H: 13.81%
C: 13.29%
positive trial results
Cytokinetics to Host Investor Call on December 27 to Discuss the Topline Results from SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy
Published: 2023-12-26 (Crawled : 21:00) - globenewswire.com
CYTK | $67.49 0.73% 0.73% 1.5M
|
Health Technology
|
| O: 61.12%
H: 13.81%
C: 13.29%
topline trial results
Cytokinetics Announces Start of ACACIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Published: 2023-09-06 (Crawled : 12:00) - globenewswire.com
CYTK | $67.49 0.73% 0.73% 1.5M
|
Health Technology
|
| O: 1.17%
H: 1.82%
C: 0.67%
start trial
Cytokinetics Announces Start of MAPLE-HCM, a Phase 3 Clinical Trial of Aficamten Compared to Metoprolol in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Published: 2023-06-20 (Crawled : 12:00) - globenewswire.com
CYTK | $67.49 0.73% 0.73% 1.5M
|
Health Technology
|
| O: -0.4%
H: 3.27%
C: 2.77%
trial
Cytokinetics Presents New Data in Patients With Non-Obstructive HCM From Cohort 4 of REDWOOD-HCM in Late-Breaking Clinical Trial Session at The European Society of Cardiology Heart Failure 2023 Congress
Published: 2023-05-20 (Crawled : 16:20) - globenewswire.com
CYTK | $67.49 0.73% 0.73% 1.5M
|
Health Technology
| Email alert
Add to watchlist
heart trial cardiology
Cytokinetics Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HFSA Annual Scientific Meeting
Published: 2022-10-02 (Crawled : 16:20) - globenewswire.com
CYTK | $67.49 0.73% 0.73% 1.5M
|
Health Technology
| Email alert
Add to watchlist
meeting trial
Cytokinetics Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HCM Society Scientific Sessions
Published: 2022-09-30 (Crawled : 15:00) - globenewswire.com
CYTK | $67.49 0.73% 0.73% 1.5M
|
Health Technology
|
| O: -0.55%
H: 3.04%
C: -0.43%
sessions trial
Cytokinetics Announces Start of SEQUOIA-HCM, a Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Published: 2022-02-23 (Crawled : 13:30) - biospace.com/
CYTK | $67.49 0.73% 0.73% 1.5M
|
Health Technology
|
| O: 0.0%
H: 1.25%
C: -6.95%
cardio trial star phase 3
Cytokinetics Announces Results From REDWOOD-HCM and GALACTIC-HF Presented in Late Breaking Clinical Trial Session at the HFSA Annual Scientific Meeting
Published: 2021-09-12 (Crawled : 16:20) - globenewswire.com
CYTK | $67.49 0.73% 0.73% 1.5M
|
Health Technology
| Email alert
Add to watchlist
results trial
Cytokinetics Announces Results From REDWOOD-HCM and GALACTIC-HF to Be Presented in Late Breaking Clinical Trials Session at the HFSA Annual Scientific Meeting
Published: 2021-08-31 (Crawled : 12:00) - globenewswire.com
CYTK | $67.49 0.73% 0.73% 1.5M
|
Health Technology
|
| O: 0.21%
H: 2.02%
C: 0.73%
clinical trials results trial
Cytokinetics Announces Start of COURAGE-ALS, a Phase 3 Clinical Trial of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis
Published: 2021-08-02 (Crawled : 12:00) - globenewswire.com
CYTK | $67.49 0.73% 0.73% 1.5M
|
Health Technology
|
| O: 2.52%
H: 1.57%
C: -3.03%
sclerosis phase 3 trial als
Cytokinetics Announces Completion of Enrollment in METEORIC-HF, The Second Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure With Reduced Ejection Fraction
Published: 2021-06-15 (Crawled : 12:00) - globenewswire.com
CYTK | $67.49 0.73% 0.73% 1.5M
|
Health Technology
|
| O: -0.23%
H: 4.68%
C: 2.2%
heart phase 3 trial enroll
Cytokinetics Announces Secondary Analysis of GALACTIC-HF Presented in Late Breaking Clinical Trial Session at the American College of Cardiology 70th Annual Scientific Session and Published in the Journal of American College of Cardiology
Published: 2021-05-17 (Crawled : 12:00) - globenewswire.com
CYTK | $67.49 0.73% 0.73% 1.5M
|
Health Technology
|
| O: -0.89%
H: 1.87%
C: -0.51%
cardiology cardio trial
Cytokinetics Announces Secondary Analysis From GALACTIC-HF to Be Presented in Late Breaking Clinical Trial Session at American College of Cardiology 70th Annual Scientific Session & Expo (ACC.21)
Published: 2021-03-18 (Crawled : 12:00) - globenewswire.com
CYTK | $67.49 0.73% 0.73% 1.5M
|
Health Technology
|
| O: 0.12%
H: 0.43%
C: -5.37%
cardiology cardio trial
Cytokinetics Announces Data and Trial Design Presented at the International Symposium on ALS/MNDAdditional Data from FORTITUDE-ALS Support Rationale and Design for COURAGE-ALS, A Planned Phase 3 Clinical Trial of Reldesemtiv in Patients with ALS
Published: 2020-12-14 (Crawled : 15:00) - biospace.com/
CYTK | $67.49 0.73% 0.73% 1.5M
|
Health Technology
|
| O: -1.62%
H: 8.25%
C: 6.15%
phase 3 trial als symposium designation
Cytokinetics Announces Data and Trial Design Presented at the International Symposium on ALS/MND
Published: 2020-12-14 (Crawled : 13:01) - globenewswire.com
CYTK | $67.49 0.73% 0.73% 1.5M
|
Health Technology
|
| O: -1.62%
H: 8.25%
C: 6.15%
trial als symposium designation
Cytokinetics Announces Additional Results From GALACTIC-HF Presented at the 17th Global Cardiovascular Clinical Trialists
Published: 2020-12-07 (Crawled : 13:00) - globenewswire.com
CYTK | $67.49 0.73% 0.73% 1.5M
|
Health Technology
|
| O: 0.06%
H: 2.1%
C: -4.79%
results cardio cardiovascular trial
Cytokinetics Announces GALACTIC-HF Accepted for Presentation In Late Breaking Clinical Trial Session At American Heart Association Scientific Sessions
Published: 2020-09-17 (Crawled : 09:33) - globenewswire.com
CYTK | $67.49 0.73% 0.73% 1.5M
|
Health Technology
|
| O: -2.51%
H: 2.42%
C: 0.18%
heart trial
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.